Eficácia e segurança da dapagliflozina no tratamento do diabetes mellitus tipo 2: Uma revisão integrativa
DOI:
https://doi.org/10.61223/coopex.v14i4.459Palavras-chave:
Diabetes Mellitus, Dapagliflozina, Eficácia, SegurançaResumo
O diabetes mellitus tipo 2 (DM2) é uma doença crônica com alta incidência global. A dapagliflozina, um inibidor do cotransportador de sódio-glicose tipo 2 (SGLT2), tem ganhado destaque como opção terapêutica no tratamento do DM2 devido aos seus efeitos hipoglicemiantes e benefícios metabólicos adicionais, como a perda de peso e redução da pressão arterial. Objetivou-se investigar a eficácia e segurança da dapagliflozina no tratamento do DM2. Trata-se de uma revisão integrativa realizada em pares e em computadores distintos. As buscas foram feitas nas bases de dados Pubmed, Web of Science e SCOPUS. Foram encontrados 13 artigos, cujos conteúdos foram agrupados em 3 temas e 5 categorias que mostraram os efeitos, benefícios e segurança da dapagliflozina. Conclui-se que a dapagliflozina tem um papel fundamental no tratamento do DM2, abrangendo um controle glicêmico eficaz e contribuição para a perda de peso, além disso, apresenta proteção renal e cardíaca que são efeitos imprescindíveis na abordagem das complicações associadas à doença.
Referências
ARAKI, E. et al. Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: results of the interim analysis of 16‐week double‐blind treatment period. Journal of diabetes investigation, v. 7, n. 4, p. 555-564, 2016.
ATLAS, IDF Diabetes et al. IDF diabetes atlas. International Diabetes Federation (9th edition). Disponivel em http://www. idf. org/about-diabetes/facts-figures, 2019.
COSTA, B. R. da; JÜNI, P. Systematic reviews and meta-analyses of randomized trials: principles and pitfalls. European heart journal, v. 35, n. 47, p. 3336-3345, 2014.
FENG, M. et al. Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Medicine, v. 98, n. 30, 2019.
FIORETTO, P. et al. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. Diabetes, Obesity and Metabolism, v. 20, n. 11, p. 2532-2540, 2018.
FRIAS, J. P. et al. Efficacy and safety of dual add‐on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: results from a 52‐week, randomized, active‐controlled trial. Diabetes, Obesity and Metabolism, v. 22, n. 7, p. 1083-1093, 2020.
FURTADO, R. H. M. et al. Efficacy and safety of dapagliflozin in type 2 diabetes according to baseline blood pressure: Observations from DECLARE-TIMI 58 trial. Circulation, v. 145, n. 21, p. 1581-1591, 2022.
HEERSPINK, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine, v. 383, n. 15, p. 1436-1446, 2020.
HEERSPINK, H. J. L. et al. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrology Dialysis Transplantation, v. 35, n. 2, p. 274-282, 2020.
HUSSAIN, M. et al. Comparison Of Efficacy And Safety Profile Of Empagliflozin Versus Dapagliflozin As Add On Therapy In Type 2 Diabetic Patients. Journal of Ayub Medical College Abbottabad-Pakistan, v. 33, n. 4, 2021.
KAKU, K. et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double‐blind, placebo‐controlled trial. Diabetes, Obesity and Metabolism, v. 15, n. 5, p. 432-440, 2013.
MÜLLER‐WIELAND, D. et al. Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, v. 20, n. 11, p. 2598-2607, 2018.
NAUCK, M. A. et al. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation, v. 136, n. 9, p. 849-870, 2017.
OYAMA, K. et al. Efficacy and safety of dapagliflozin according to background use of cardiovascular medications in patients with type 2 diabetes: a prespecified secondary analysis of a randomized clinical trial. JAMA cardiology, v. 7, n. 9, p. 914-923, 2022.
SCOTT, R. et al. A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT‐R study. Diabetes, Obesity and Metabolism, v. 20, n. 12, p. 2876-2884, 2018.
SONNE, D. P.; HEMMINGSEN, B. Comment on American Diabetes Association. Standards of Medical Care in Diabetes—2017. Diabetes Care 2017; 40 (Suppl. 1): S1–S135. Diabetes care, v. 40, n. 7, p. e92-e93, 2017.
STONE, P. W. Popping the (PICO) question in research and evidence-based practice. Applied nursing research: ANR, v. 15, n. 3, p. 197-198, 2002.
WAIJER, S. W. et al. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. Diabetologia, v. 65, n. 7, p. 1085-1097, 2022.
WHEELER, D. C. et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrology Dialysis Transplantation, v. 35, n. 10, p. 1700-1711, 2020.
WILDING, J. P. H. et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. International journal of clinical practice, v. 67, n. 12, p. 1267-1282, 2013.
WIVIOTT, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, v. 380, n. 4, p. 347-357, 2019.
ZACCARDI, F. et al. Efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis. Diabetes, Obesity and Metabolism, v. 18, n. 8, p. 783-794, 2016.
ZELNIKER, T. A. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet, v. 393, n. 10166, p. 31-39, 2019.
Downloads
Publicado
Como Citar
Licença
Copyright (c) 2023 Igor Queiroz Macêdo Barbosa, Rosimery Cruz de Oliveira Dantas
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Creative Commons 
.png){kind=logo}
